Andrew Lo on Muck Rack

Andrew Lo

As seen in: Medium, Nature, Wiley Online Library, Aol, MIT News, MIT Sloan Management Review, PBS NewsHour, PLOS, PLOS ONE, The MIT Press and
Tech • Gadgets • Cars • SimRacer • #FinTech • #InsurTech • Public Speaker • CEO, Embark
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andrew

Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A lição de US$ 3,4 bi que as farmacêuticas devem aprender e que pode salvar milhões

|
By Annette Bakker, Andrew Lo
| InfoMoney Verified
Para pacientes que vivem com doenças raras e negligenciadas, o próximo tratamento inovador pode já estar guardado em uma gaveta de uma empresa farmacêutica. A Pfizer certa vez engavetou um medicamento experimental contra o câncer. Então, a Children’s Tumor Foundation entrou em contato. As duas organizações reconheceram que o composto poderia combater tumores causados por um distúrbio genético raro, então a Pfizer o licenciou para uma nova spin-off, a SpringWorks Therapeutics.
Open in Who Shared Issue with article?

The $3.4 billion lesson Big Pharma needs to learn: its shelved drugs could save millions of patients

|
By Annette Bakker, Andrew Lo
| Yahoo Finance Verified
For patients living with rare and neglected diseases, the next breakthrough treatment might already be sitting in a pharmaceutical company’s filing cabinet. Pfizer once shelved an experimental cancer drug. Then the Children’s Tumor Foundation came knocking. The two organizations recognized the compound could fight tumors caused by a rare genetic disorder, so Pfizer licensed it to a new spin-off, SpringWorks Therapeutics.
Open in Who Shared View Duplicates (5) Issue with article?

Establishing a commercial solution for extremely rare genetic diseases - Nature Biotechnology

|
By Stanley T. Crooke, Andrew Lo
| Nature Verified
While extremely rare genetic diseases have been present in humans throughout history, only now because of advances in genomic sequencing are the prevalence, characteristics, scale and impact of such diseases becoming apparent. It is estimated that there are 300 million humans affected by rare diseases1, and it is highly likely that there are tens of millions of patients with extremely rare pathogenic mutations.
Open in Who Shared Issue with article?
See all 296 licensed articles (308 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified